Fractyl Health outlines 2026 milestones for Revita and Rejuva; cash $85.6M

FRACTYL HEALTH, INC.

Preliminary unaudited cash $81.5M at Dec 31, 2025; plus $4.1M from Tranche A warrant exercises on Jan 2, 2026 gives $85.6M.
Revita: 6-month randomized REMAIN-1 Midpoint data due late Jan 2026; potential PMA filing in H2 2026.
Rejuva: RJVA-001 first-in-human dosing expected in H2 2026 subject to CTA authorization; regulatory feedback in Q2 2026.
Cash runway projected through early 2027 to fund all planned 2026 clinical and regulatory milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.